Carnitine palmitoyltransferase (CPT) is the central rate-limiting enzyme system for mitochondrial fatty acid β-oxidation, capable of converting palmitoyl-CoA into palmitoylcarnitine[1][2]. CPT transports long-chain acyl-CoA into the mitochondrial matrix, where it undergoes a transesterification reaction with free carnitine to generate acylcarnitine—the sole form in which long-chain fatty acids can traverse the mitochondrial inner membrane. The complete carnitine cycle is cooperatively executed by CPT1 on the mitochondrial outer membrane, CPT2 on the inner face of the inner membrane, and carnitine-acylcarnitine translocase (CACT), which mediates the exchange of acylcarnitine and free carnitine across the inner membrane. The activity of CPT directly determines the efficiency of cellular fatty acid oxidation[3][4]. The CPT1 enzyme system comprises three major isoforms: CPT1A (liver isoform), CPT1B (muscle isoform), and CPT1C (brain isoform). These isoforms exhibit significant differences in tissue distribution, functional regulation, and physiological and pathological roles, collectively constituting a complex metabolic regulatory network. In metabolic diseases (such as non-alcoholic steatohepatitis and obesity), the downregulation of CPT1A expression impairs fatty acid oxidation, thereby triggering lipid accumulation; conversely, in various malignancies, CPT1A is frequently overexpressed, providing energy for tumor cell proliferation and mediating drug resistance, thus serving as a critical node in metabolic reprogramming[3][4]. CPT1A activity is primarily subject to physiological inhibition by malonyl-CoA; however, under pathological conditions, it is subject to transcriptional regulation by various signaling pathways, including JAK2/STAT3 and AMPK. Furthermore, recent studies have revealed that CPT1A possesses non-metabolic functions, such as the regulation of histone acetylation. Intervention strategies targeting CPT vary markedly depending on the specific disease context: in metabolic disorders, activating CPT1A is required to enhance fatty acid oxidation—a process that can be upregulated, for instance, by the traditional Chinese medicine compound *Qushi Huayu* formula; conversely, in anti-tumor research, inhibiting CPT1A may be necessary to disrupt the energy supply, with inhibitors such as DHP-B having already demonstrated promising anti-tumor efficacy[1][2]. The CPT system has emerged as a pivotal molecular link connecting lipid metabolism with cell fate, positioning itself at the nexus—and as a major research hotspot—across diverse fields including metabolism, signal transduction, epigenetics, immunology, tumor biology, and precision medicine[1][2][3][4].
( )-C75 是 C75 (MS-M55858) 的一种异构体,而 C75 是一种合成的脂肪酸合成酶 (FASN) 抑制剂,抑制前列腺癌细胞 PC3 的 IC50 值为 35 μM,并且是有效的 CPT1A 激活剂。
1,3-Palmitin-2-docosahexaenoin(1,3-Dipalmitoyl-2-docosahexaenoyl glycerol)是一种三酰甘油 (TAG) 异构体,其 docosahexaenoic acid (DHA) 位于甘油骨架的 β 位 (sn-2),可抑制脂肪酸合酶和胆固醇代谢酶、在肝线粒体中激活肉碱棕榈酰转移酶 (CPT) 以促进脂肪酸的 β-氧化,并具有脂质代谢调节活性。
Alisol A 24-acetate(Alisol A monoacetate)是一种口服活性的原萜烷型四环三萜类化合物衍生物,可上调脂联素、AMPKα、CPT1、ACOX1,下调SREBP-1c、ACC、FAS、Bcl-2、Bcl-xl、PPAR-γ、perilipin A及NFATc1的表达,抑制PI3K/Akt/mTOR及HMGR的活性,激活PKA和ERK信号通路,并调控细胞凋亡(apoptosis)、自噬(Autophagy)、肝脏脂质蓄积、炎症反应、神经保护、MRSA膜完整性以及破骨细胞分化,因此可用于非酒精性脂肪肝病、肾毒性、肥胖症、全脑缺血再灌注损伤、细菌感染及骨质疏松症的相关研究。
9(S)-HOTrE 是一种 PPARα 激活剂和载脂蛋白 A-I (apoA-I) mRNA 表达诱导剂,可上调 PPARα 靶基因 CPT1α 的表达,并可用于心血管疾病的研究。
C75 是一种合成的脂肪酸合成酶 (FASN) 抑制剂,对前列腺癌细胞 PC3 的 IC50 值为 35 μM,同时也是有效的 CPT1A 激活剂。
C75 (Standard) 是 C75 的分析标准品,用于研究及分析应用,C75 是一种合成的脂肪酸合成酶 (FASN) 抑制剂,对前列腺癌细胞 PC3 的 IC50 值为 35 μM,同时也是有效的 CPT1A 激活剂。
DGAT-1 inhibitor 2 是一种口服活性 DGAT-1 抑制剂,对人 DGAT-1 和大鼠 DGAT-1 的 IC50 值分别为 15 nM 和 9 nM,可增加 ROS 浓度以及 GRP78 和 PERK 的蛋白丰度,增加脂肪酸处理细胞中 SREBF1、CPT1A 和 MTTP 的 mRNA,并改善肥胖。
DGAT-1 inhibitor 2 (Standard) 是 DGAT-1 inhibitor 2 (MS-O64468) 的分析标准品,用于研究及分析应用;DGAT-1 inhibitor 2 是一种口服活性 DGAT-1 抑制剂,对人 DGAT-1 和大鼠 DGAT-1 的 IC50 值分别为 15 nM 和 9 nM,可增加 ROS 浓度及 GRP78、PERK 的蛋白丰度,增加脂肪酸处理的细胞中 SREBF1、CPT1A 和 MTTP 的 mRNA,并改善肥胖。
Diphenyl Phosphate 以性别特异性方式抑制斑马鱼和小鼠的生长和能量代谢,被证实可抑制 SDH (respiratory complex II) 活性、降低 CPT1 蛋白表达并破坏线粒体膜完整性,因此可用于代谢疾病领域研究。
Carbacyclin 是 PGI2 的类似物,作为前列腺环素 (prostacyclin (PGI2)) 受体激动剂和血管舒张剂,能够有效抑制血小板聚集,同时可通过 PPARδ 诱导 CPT-1 mRNA 表达,且不依赖 IP 受体信号通路。
Isorhapontigenin 是一种具有口服活性的膳食多酚,作为强效抗氧化剂能够减弱活性氧 (ROS) 的生成,可促进 JUN 与 SESN2 启动子的 AP-1 位点结合、诱导 SESN2 转录、触发依赖 MAPK8 的 JUN 激活,并上调 PPAR-α、PGC-1α、CPT-1A 的表达以促进脂肪酸氧化,同时可诱导自噬 (autophagy)、细胞凋亡 (apoptosis) 及前脂肪细胞分化,抑制肿瘤生长、细胞侵袭、NF-κB 转录活性、P3K/Akt 信号通路、STAT1 磷酸化及 MMP-2 表达,并可减轻氧化应激、炎症细胞因子释放、甘油三酯蓄积,提升细胞内 ATP 水平并促进 Nrf2 核转位,从而改善脂肪组织的胰岛素敏感性、葡萄糖耐量,降低餐后血糖、胰岛素及游离脂肪酸水平,可用于膀胱癌、肝损伤、慢性阻塞性肺疾病、急性肺损伤和 2 型糖尿病的相关研究。